Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Giapreza

Last reviewed on RxList: 9/18/2020
Giapreza Side Effects Center

Last reviewed on RxList 10/01/2019

Giapreza (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. Common side effects of Giapreza include:

The starting dose of Giapreza is 20 nanograms (ng)/kg/min administered intravenously. The dose is adjusted as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed. Giapreza may interact with angiotensin converting enzyme (ACE) inhibitors and angiotensin II blockers (ARBs). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Giapreza; it is unknown if it would affect a fetus. It is unknown if Giapreza passes into breast milk. Consult your doctor before breastfeeding.

Our Giapreza (angiotensin II) Injection for Intravenous Infusion Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

8 First Aid Kit Essentials for Scrapes, Cuts, Bug Bites, and More in Pictures See Slideshow
Giapreza Professional Information

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

ATHOS-3

The safety of GIAPREZA was evaluated in ATHOS-3 [see WARNINGS AND PRECAUTIONS]. Patients in ATHOS-3 were receiving other vasopressors in addition to GIAPREZA or placebo, which were titrated to effect on mean arterial pressure (MAP).

Table 2 summarizes adverse reactions with an incidence of at least 4% among patients treated with GIAPREZA and with a rate of at least 1.5% higher with GIAPREZA than with placebo.

Table 2: Adverse Reactions Occurring in ≥ 4% of Patients Treated with GIAPREZA and ≥ 1.5% More Often than in Placebo-treated Patients in ATHOS-3

Adverse Event GIAPREZA
N=163
Placebo
N=158
Thromboembolic eventsa 21 (12.9%) 8 (5.1%)
Deep vein thrombosis 7 (4.3%) 0 (0.0%)
Thrombocytopenia 16 (9.8%) 11 (7.0%)
Tachycardia 14 (8.6%) 9 (5.7%)
Fungal infection 10 (6.1%) 2 (1.3%)
Delirium 9 (5.5%) 1 (0.6%)
Acidosis 9 (5.5%) 1 (0.6%)
Hyperglycemia 7 (4.3%) 4 (2.5%)
Peripheral ischemia 7 (4.3%) 4 (2.5%)
a Including arterial and venous thrombotic events

Read the entire FDA prescribing information for Giapreza (Angiotensin II Injection for Infusion)

QUESTION

Emotional trauma is best described as a psychological response to a deeply distressing or life-threatening experience. See Answer
Related Resources for Giapreza

© Giapreza Patient Information is supplied by Cerner Multum, Inc. and Giapreza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW